<div><div></div><div>Indaptus Therapeutics appointed Tim Ruan and Yi Zhang as independent directors effective April 22, 2026, and reported the resignation of director Matthew McMurdo effective April 22, 2026.<div><table><tbody><tr><td>Individual</td><td>Tim Ruan</td><td>Yi Zhang (Johnny)</td><td>Matthew McMurdo</td></tr><tr><td>Role</td><td>Independent Director; Audit Committee member; Audit committee financial expert</td><td>Independent Director; Nominating Committee member</td><td>Director</td></tr><tr><td>Type of Change</td><td>Appointed</td><td>Appointed</td><td>Resigned</td></tr><tr><td>Effective Date</td><td>April 22, 2026</td><td>April 22, 2026</td><td>April 22, 2026</td></tr><tr><td>Reason</td><td>Not disclosed</td><td>Not disclosed</td><td>Resignation not due to any disagreement with the Company on operations, policies or practices</td></tr><tr><td>Replacement Info</td><td>Not disclosed</td><td>Not disclosed</td><td>Not disclosed</td></tr><tr><td>Background Details</td><td>40-year-old financial executive; CFO of Ocumension Therapeutics; former Exec. Director at Goldman Sachs (Asia) and VP at Morgan Stanley Asia; MS in Biotechnology (HKUST); BCom (Finance) and LLB (UNSW)</td><td>48-year-old IP and life sciences expert; Partner at JunHe; registered U.S. patent attorney; Ph.D. in Molecular, Cellular &amp; Developmental Biology (Iowa State); J.D. (Georgetown)</td><td>Not disclosed</td></tr><tr><td>Board/Committee Role Changes</td><td>Appointed to Audit Committee; qualifies as audit committee financial expert</td><td>Appointed to Nominating Committee</td><td>Not disclosed</td></tr></tbody></table></div>Original SEC Filing: Indaptus Therapeutics, Inc. [ INDP ] - 8-K - Apr. 22, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

INDP

LABU

ARKG

Indaptus Therapeutics has appointed Tim Ruan and Yi Zhang as independent directors, effective April 22, 2026, while Matthew McMurdo has resigned from the board on the same date. Ruan, a financial executive and CFO of Ocumension Therapeutics, will serve on the Audit Committee, while Zhang, an IP and life sciences expert, will join the Nominating Committee. McMurdo's resignation was not due to any disagreements with the company.

TradingView

Indaptus Therapeutics

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns